News & analysis on the clinical development and manufacture of large molecule drugs
Lonza has launched the next generation of its Nucleofector Platform
By Jane Byrne
- Last updated on
Lonza had released the 'next-generation' 4D-Nucleofector Platform, what it describes as the leading non-viral cell transfection method for a wide variety of cell types – even those traditionally hard to transfect.
It says the modular design of the new tech offers unmatched flexibility in scale and throughput with proven performance.
This 4D-Nucleofector Core Unit comes with a user experience upgrade for "even more intuitive" experimental setup, added Lonza.
“For more than 20 years, Nucleofector Technology has led the market as the most effective non-viral cell transfection method, which can be used even for hard-to-transfect cells, such as primary cells and pluripotent stem cells. Now, with an updated core unit and even more intuitive software, the next generation 4D-Nucleofector Platform delivers flexibility and the same trusted performance with even greater ease of use."
According to the company, the 4D-Nucleofector Core Unit can operate up to three functional modules, allowing for tailored experimental setups and facilitating scale-up from low to high-volume transfection. In the next generation technology, the family of units is now joined by a fully integrated 96-well unit to suit users with mid-scale transfection requirements for up to 96 samples at once, it added.
In addition, the updated core unit features an 8-inch touchscreen display, enabling users to easily set up their experiments and control all functional modules via the system’s intuitive and user-friendly software, explained Lonza.
Furthermore, optimized protocols are available for more than 750 different cell types and are designed to provide robust transfection conditions, said the company.